On January 23rd, Sanofi announced on its official website that it had reached a final agreement with biopharmaceutical listed company Inhibrx. According to the agreement, Sanofi agreed to acquire Inhibrx after divesting non INBRX-101 assets into the new Inhibrx company.
According to the agreement, shareholders of Inhibrx will receive $30.0 in cash, $5.0 in contingent value (CVR), and 0.25 shares of newly listed company shares for each share held by Inhibrx. The newly listed company will retain Inhibrx's non INBRX-101 assets.
It is understood that INBRX-101 is an optimized recombinant human AAT-Fc fusion protein used for the treatment of various diseases α- Patients with emphysema caused by anti trypsin deficiency (AATD).